We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+39.65%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.14B
AUM Growth
+$662M
Cap. Flow
+$228M
Cap. Flow %
10.65%
Top 10 Hldgs %
66.06%
Holding
37
New
6
Increased
15
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$137M
2
ARGX icon
argenx
ARGX
+$75.1M
3
IRON icon
Disc Medicine
IRON
+$57M
4
ASND icon
Ascendis Pharma A/S
ASND
+$35.1M
5
ACLX
Arcellx
ACLX
+$31.8M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$69.4M
2
INCY icon
Incyte
INCY
+$52.7M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$34.7M
4
TGTX icon
TG Therapeutics
TGTX
+$16.8M
5
VRNA
Verona Pharma
VRNA
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$284M 13.29%
3,858,008
+2,219,861
+136% +$137M
ACLX
2
DELISTED
Arcellx
ACLX
$203M 9.51%
3,658,624
+705,502
+24% +$31.8M
ARGX icon
3
argenx
ARGX
$57.4B
$161M 7.53%
422,577
+161,134
+62% +$75.1M
IRON icon
4
Disc Medicine
IRON
$2.83B
$138M 6.45%
2,385,857
+1,113,578
+88% +$57M
LEGN icon
5
Legend Biotech
LEGN
$4.3B
$114M 5.34%
1,894,644
-130,836
-6% -$8.29M
OLMA icon
6
Olema Pharmaceuticals
OLMA
$1.02B
$111M 5.19%
7,903,600
+100,000
+1% +$1.34M
VRDN icon
7
Viridian Therapeutics
VRDN
$2.13B
$104M 4.89%
4,794,488
+1,112,741
+30% +$17.6M
IMCR icon
8
Immunocore
IMCR
$1.78B
$99.3M 4.65%
1,453,883
+69,197
+5% +$3.6M
CERE
9
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$98.8M 4.63%
2,330,508
-202,464
-8% -$5.82M
XENE icon
10
Xenon Pharmaceuticals
XENE
$6.32B
$98M 4.59%
2,127,400
+635,565
+43% +$22.5M
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$90.7M 4.24%
1,543,116
-125,000
-7% -$7.03M
CRNX icon
12
Crinetics Pharmaceuticals
CRNX
$8.86B
$82.3M 3.85%
2,312,919
+134,182
+6% +$4.11M
AUTL
13
Autolus Therapeutics
AUTL
$386M
$81.2M 3.8%
12,611,335
-1,795,447
-12% -$6.85M
BCYC
14
Bicycle Therapeutics
BCYC
$270M
$67M 3.14%
3,707,001
+64,694
+2% +$1.07M
AMAM
15
DELISTED
Ambrx Biopharma Inc
AMAM
$62M 2.9%
4,352,689
+864,093
+25% +$9.82M
ALPN
16
DELISTED
Alpine Immune Sciences Inc
ALPN
$60.5M 2.83%
3,176,743
+755,000
+31% +$10.5M
ASND icon
17
Ascendis Pharma A/S
ASND
$16.7B
$44.3M 2.07%
+351,700
New +$35.1M
ARVN icon
18
Arvinas
ARVN
$518M
$38.3M 1.79%
+931,303
New +$21.8M
TGTX icon
19
TG Therapeutics
TGTX
$8.58B
$37.1M 1.74%
2,171,419
-1,447,596
-40% -$16.8M
ZLAB icon
20
Zai Lab
ZLAB
$2.17B
$29.8M 1.4%
1,091,779
-50,604
-4% -$1.34M
IMTX icon
21
Immatics
IMTX
$1.24B
$22.5M 1.05%
2,136,339
+77,892
+4% +$717K
TARS icon
22
Tarsus Pharmaceuticals
TARS
$2.56B
$20.8M 0.97%
+1,025,000
New +$17.1M
CMPS
23
Compass Pathways
CMPS
$1.52B
$19.8M 0.93%
2,265,988
+907,279
+67% +$5.87M
KURA icon
24
Kura Oncology
KURA
$922M
$18.2M 0.85%
1,262,828
+50,000
+4% +$492K
CRBU icon
25
Caribou Biosciences
CRBU
$156M
$16.8M 0.78%
2,923,851
-20,662
-0.7% -$102K
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $4.87B AUM 25.35% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MSRPS
Maryland State Retirement & Pension System Baltimore, Maryland $4.92B AUM 28.48% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return

Paradigm Biocapital Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Paradigm Biocapital Advisors held 37 positions worth $2.14B, up 45% from $1.47B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Paradigm Biocapital Advisors deployed $228M of net new capital in Q4 2023, opening 6 new positions and adding to 15 existing holdings. Its largest new stake was Ascendis Pharma A/S: 351,700 shares worth $44.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was TG Therapeutics, an estimated $16.8M trimmed.

  • Paradigm Biocapital Advisors's largest Q4 2023 buy was Ascendis Pharma A/S: 351,700 shares worth $44.3M.
  • Paradigm Biocapital Advisors added most to Nuvalent in Q4 2023, an estimated $137M increase.
  • Paradigm Biocapital Advisors's biggest Q4 2023 reduction was TG Therapeutics, cutting an estimated $16.8M.
  • Paradigm Biocapital Advisors fully exited United Therapeutics in Q4 2023, selling an estimated $69.4M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 66% of its $2.14B portfolio in Q4 2023.
  • Paradigm Biocapital Advisors opened 6 new positions and closed 7 in Q4 2023.
  • Paradigm Biocapital Advisors's portfolio value rose 45% quarter-over-quarter to $2.14B.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.